Neville Rodie & Shaw Inc. held its stake in shares of Shire PLC (NASDAQ:SHPG) during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 5,218 shares of the biopharmaceutical company’s stock at the end of the first quarter. Neville Rodie & Shaw Inc.’s holdings in Shire PLC were worth $909,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Thornburg Investment Management Inc. increased its position in Shire PLC by 0.4% in the first quarter. Thornburg Investment Management Inc. now owns 116,566 shares of the biopharmaceutical company’s stock valued at $20,309,000 after buying an additional 431 shares during the last quarter. Lockheed Martin Investment Management Co. increased its position in Shire PLC by 150.0% in the first quarter. Lockheed Martin Investment Management Co. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $5,227,000 after buying an additional 18,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Shire PLC by 107.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,881 shares of the biopharmaceutical company’s stock valued at $501,000 after buying an additional 1,492 shares during the last quarter. Catalyst Capital Advisors LLC increased its position in Shire PLC by 21.9% in the first quarter. Catalyst Capital Advisors LLC now owns 1,473 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 265 shares during the last quarter. Finally, Trexquant Investment LP purchased a new position in Shire PLC during the first quarter valued at approximately $1,132,000. Hedge funds and other institutional investors own 21.28% of the company’s stock.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Shire PLC (SHPG) traded up 1.46% during trading on Friday, hitting $164.72. The company’s stock had a trading volume of 1,542,493 shares. The company has a 50-day moving average of $177.23 and a 200 day moving average of $174.21. Shire PLC has a one year low of $161.09 and a one year high of $209.22. The firm has a market cap of $49.06 billion, a PE ratio of 168.94 and a beta of 1.57.

Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.22 by $0.41. The firm had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The company’s revenue for the quarter was up 109.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.12 earnings per share. On average, equities analysts forecast that Shire PLC will post $14.90 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/06/16/shire-plc-shpg-position-maintained-by-neville-rodie-shaw-inc-updated-updated.html.

SHPG has been the topic of several research reports. Royal Bank of Canada set a $221.00 price objective on Shire PLC and gave the stock a “buy” rating in a report on Thursday, May 18th. Jefferies Group LLC set a $239.00 target price on Shire PLC and gave the company a “buy” rating in a research report on Thursday, April 20th. Liberum Capital started coverage on Shire PLC in a research report on Thursday, March 9th. They set a “buy” rating on the stock. Stifel Nicolaus dropped their target price on Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “conviction-buy” rating on shares of Shire PLC in a research report on Friday, April 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $223.01.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.